



LISTING OF CLAIMS

1. (Currently amended) An oral contraceptive composition for administration to the male comprising a compound of the formula





or




wherein X is P or S;

R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation or



R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;

R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;


R<sub>6</sub> is H or C<sub>1</sub>-C<sub>13</sub> alkyl; and

Y=O or NH and a pharmaceutically acceptable carrier suitable for oral delivery.


2. (Previously presented) The composition of claim 1 wherein the composition is formulated as tablet or capsule.

3. (Previously presented) The composition of claim 1 wherein the composition is formulated as a gelcap or suspension.

4. (Previously presented) The composition of claim 1 wherein the compound has the general formula



wherein R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkoxy, or



and Y is O.

5. (Previously presented) The composition of claim 4 wherein

R is C<sub>10</sub>-C<sub>18</sub> alkyl;

R<sub>1</sub> is a pharmaceutically acceptable cation or



and L is 20.


6. (Previously presented) The composition of claim 4 wherein R is



R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl; and

R<sub>1</sub> is a pharmaceutically acceptable cation.

7. (Previously presented) The composition of claim 1 wherein the compound has the general formula



wherein R is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy; and

$R_1$  and  $R_5$  are independently H or a pharmaceutically acceptable cation.


8. (Previously presented) The composition of claim 7 wherein

$R$  is  $C_4-C_{24}$  alkoxy;

$R_1$  is H or a pharmaceutically acceptable cation; and

$R_5$  is H.

9. (Previously presented) The contraceptive composition of claim 1 wherein the compound has the general formula:




wherein X is P or S;

M is a cation; and

$R$  is  $C_4-C_{24}$  alkyl,  $C_4-C_{24}$  alkenyl,  $C_4-C_{24}$  alkoxy,



or



wherein  $n = 2, 3$  or  $4$ ;

$R_2 = C_9-C_{13}$  alkyl; and

$R_3 = C_4-C_{24}$  alkyl,


10. (Previously presented) The composition of claim 9 wherein X is S.

11. (Previously presented) The composition of claim 9 wherein the composition is formulated as tablet or capsule.

12. (Previously presented) The composition of claim 9 wherein the composition is formulated as a Gelcap or suspension.


13. (Previously presented) The composition of claim 10 wherein the cation is sodium.

14. (Currently amended) A contraceptive transdermal patch or implant for administration to the male, wherein said patch or implant comprises a composition comprising a compound of the general formula:




wherein X is P or S;

R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation



wherein L is 4 to 24;

R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub>, is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;


R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;

R<sub>6</sub> is C<sub>1</sub>-C<sub>13</sub> alkyl; and

Y = O or NH.


14. 15. (Currently amended) A method of inhibiting the capacitation of sperm cells,

said method comprising the steps of contacting in a male the sperm cells with a composition comprising a compound of the general formula:



wherein X is P or S;

R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation or



wherein L is 4 to 24;

R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;

R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;


R<sub>6</sub> is C<sub>1</sub>-C<sub>13</sub> alkyl; and

Y = O or NH and a pharmaceutically acceptable carrier.

15. 16. (Currently amended – cancelled) The method of claim 14 wherein the step of contacting the sperm cells with the compound occurs *in vivo* in the male.


16. 17. (Currently amended) A method for inhibiting contraception, comprising

administering to a male an effective amount of a pharmaceutically acceptable cationic salt of a compound of the general formula:




wherein X is P or S;

R is C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation or



wherein L is 4 to 24;

R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;

R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;

R<sub>6</sub> is C<sub>1</sub>-C<sub>13</sub> alkyl;

Y = O or NH.

47. 18. (Currently amended) The method of claim 46 17 wherein the composition is administered orally in a daily dosage form.

48. 19. (Currently amended) The method of claim 46 17 wherein the composition is

administered transdermally or subcutaneously to maintain constant systemic levels. for an extended time period.